24 . November , 2017 - Friday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Ibandronate Sodium

Big Image Pronouncation: (i-BAN-droh-nate SO-dee-um)
Class: Bisphosphonate

Trade Names:
Boniva
- Tablets 2.5 mg
- Tablets 150 mg
- Injection 1 mg/mL

Mechanism of Action

Pharmacology

Inhibits osteoclast activity and reduces bone resorption and turnover.

Pharmacokinetics

Absorption

Absorption from an oral dose is in the upper GI tract. Plasma level increase is dose related up to 50 mg orally and nonlinearly above that dose. After an oral dose, the time to C max is 0.5 to 2 h. Compared with IV administration, oral bioavailability is 0.6%. When coadministered with food, bioavailability may be decreased 90%.

Distribution

Rapidly binds to bone or is excreted in the urine. Vd is at least 90 L. The amount removed from circulation via bone is estimated to be 40% to 50%.

Metabolism

No evidence of metabolism.

Elimination

Cl is 84 to 160 mL/min. The portion not removed from the circulation via bone absorption (approximately 50% to 60% of absorbed dose) is eliminated unchanged by the kidney. Unabsorbed drug is eliminated unchanged in the feces.

Special Populations

Renal Function Impairment

Increased exposure (AUC ) may occur.

Indications and Usage

Treatment (injection, tablets) and prevention (tablets) of osteoporosis in postmenopausal women.

Unlabeled Uses

Treatment of metastatic bone disease in breast cancer.

Contraindications

Inability to stand or sit upright for at least 60 min (tablets); uncorrected hypocalcemia (injection, tablets); hypersensitivity to any component of the product (injection, tablets).

Dosage and Administration

Adults

PO 2.5 mg once daily or one 150 mg tablet once monthly on the same date of each month. Take at least 60 min before the first food or drink (other than water) of the day or before taking any oral medication or supplement, including antacids, calcium, or vitamins.

Adults

IV 3 mg every 3 mo administered over 15 to 30 sec.

General Advice

  • Tablets
  • Two tablet strengths are available (2.5 mg tablet for once-daily administration and 150 mg tablet for once-monthly administration). Carefully check tablet to ensure proper dose is being administered.
  • Do not administer tablets with any liquid other than plain water. Administration of ibandronate tablets with food, medication, juices, mineral water, coffee, or any other beverage will reduce ibandronate absorption and efficacy.
  • Injection
  • Injection must be administered IV by a health care provider.
  • Administer injection using the enclosed needle.
  • Prefilled syringes are for single use only; discard unused portion.
  • Do not mix injection with calcium-containing solutions or other IV administered drugs.
  • If a dose is missed, administer injection as soon as it can be rescheduled. Schedule subsequent injections every 3 mo from the date of last injection and not more frequently than once every 3 mo.
  • Patient must receive supplemental calcium and vitamin D.

Storage/Stability

Store tablets and injection at controlled room temperature (59° to 86°F).

Drug Interactions

Antacids, calcium supplements, products containing calcium, or other multivalent cations (eg, aluminum, iron, magnesium)

May interfere with oral absorption of ibandronate. Take ibandronate tablets at least 60 min before any oral medication containing multivalent cations.

Aspirin, NSAIDs

Possible additive GI adverse reactions.

Laboratory Test Interactions

May interfere with bone-imaging agents.

Adverse Reactions

The overall safety and tolerability profiles of the oral and IV dosage forms are similar.

Cardiovascular

Hypertension (7%).

CNS

Headache (7%); asthenia, dizziness (4%); fatigue, insomnia, vertigo (3%); depression, nerve root lesion (2%).

Dermatologic

Rash (3%).

EENT

Nasopharyngitis (6%); pharyngitis (3%); ocular inflammation.

GI

Dyspepsia (12%); abdominal pain (8%); diarrhea (7%); nausea (5%); constipation, tooth disorder (4%); gastroenteritis, vomiting (3%); gastritis (2%); dysphagia, esophageal and gastric ulcer, esophagitis (postmarketing).

Genitourinary

UTI (6%); cystitis (3%).

Local

Redness, swelling (less than 2%).

Metabolic-Nutritional

Hypercholesterolemia (5%).

Musculoskeletal

Back pain (14%); arthralgia (10%); myalgia (6%); joint disorder, pain in extremity (4%); arthritis, localized osteoarthritis (3%); muscle cramp (2%); incapacitating bone, joint, or muscle pain (postmarketing).

Respiratory

Upper respiratory infection (34%); bronchitis (10%); pneumonia (6%).

Miscellaneous

Acute phase reaction (oral 4%; injection 10%); influenza, pain in extremities (8%); flu-like symptoms (5%); infection (4%); allergic reactions (3%).

Precautions

Monitor

Monitor patient for signs or symptoms of esophageal reaction (eg, dysphagia, new or worsening heartburn, retrosternal pain). Discontinue therapy if noted or suspected.


Pregnancy

Category C .

Lactation

Undetermined.

Children

Safety and efficacy not established.

Hypocalcemia, hypovitaminosis D, bone mineral disturbances

Treat effectively before starting therapy with ibandronate. Ibandronate injection may cause a transient decrease in serum calcium levels.

Osteonecrosis

Osteonecrosis, primarily in the jaw, has been reported in patients receiving bisphosphonates.

Renal function impairment

Not recommended for use in patients with severe renal function impairment (CrCl less than 30 mL/min).

Overdosage

Symptoms

Hypomagnesemia, hypophosphatemia, possible hypocalcemia, upper GI adverse reactions, including dyspepsia, esophagitis, gastritis, ulcer, or upset stomach.

Patient Information

  • Advise patient to read patient information leaflet before starting therapy and with each refill.
  • Instruct patient to take each tablet with plain water immediately upon arising for the day, at least 60 min before the first food, beverage, medication, or supplement (including calcium and vitamins) of the day, and to remain in a standing or sitting position for at least 60 min.
  • Instruct patient to swallow tablet whole with a full glass (6 to 8 oz) of plain water. Caution patient not to chew or suck on tablet.
  • Caution patient not to take the tablets with any liquid other than plain water. Advise patient that taking the tablets with food, other medications, juices, mineral water, coffee, or any other beverage will reduce the absorption of ibandronate and reduce its effectiveness.
  • Advise patient taking once-monthly ibandronate 150 mg tablet to take the tablet on the same date each month.
  • Advise patient taking ibandronate once a month that if the once-monthly dose is missed and the next scheduled dose is more than 7 days away, to take their ibandronate tablet in the morning after the date that it is remembered and then return to taking 1 ibandronate tablet in the morning of their chosen day, according to their original schedule.
  • Advise patient taking ibandronate once a month that if the once-monthly dose is missed, and the next scheduled dose is only 1 to 7 days away, to skip the missed dose and take the next ibandronate tablet in the morning of the patient's chosen day, according to patient's original schedule.
  • Caution patient using 150 mg tablet to never take 2 tablets within the same week.
  • Instruct patient to discontinue therapy and seek medical care if any of the following occur: difficulty swallowing, new or worsening heartburn, pain behind breastbone.
  • Advise patient regarding interventions that help prevent osteoporosis: calcium 1,500 mg/day (diet and supplements); vitamin D supplementation; weight-bearing exercise; reduction of cigarette smoking and alcohol consumption.

Recent Drug Updates at DrugIndexOnline:





Acetaminophen/Diphenhydramine/Phenylephrine Suspension Acetaminophen/Diphenhydramine/Phenylephrine Suspension
Generic Name: Acetaminophen/Diphenhydramine/Phenylephrine Suspension (a-SEET-a-MIN-oh-fen/DYE-fen-HYE-dra-meen/FEN-il-EF-rin) Brand Name: Tylenol Children's Plus Cold and AllergyAcetaminophen/Diphenhydramine/Phenylephrine Suspension is used for:Relieving symptoms such as pain, sinus congestion, more...

Acetic Acid Gel Acetic Acid Gel
Generic Name: Acetic Acid Vaginal Gel (a-SEE-tik) Brand Name: Acid JellyAcetic Acid Gel is used for:Restoring and maintaining normal vaginal acidity. Acetic Acid Gel is a buffered vaginal acid jelly. It works by maintaining the pH (acidity) in the vagina through its buffer action. Do NOT use Ace more...

Activella Activella
Generic Name: estradiol and norethindrone acetate Dosage Form: Tablets 1.0 mg/0.5 mg 0.5 mg/0.1 mg CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS, Ca more...

Alemtuzumab Alemtuzumab
Pronouncation: (ah-lem-TOO-ze-mab) Class: Monoclonal antibody Trade Names: Campath - Sterile, preservative-free solution for injection 30 mg/ mL Mechanism of Action Pharmacology Alemtuzumab is a recombinant DNA-derived humanized monoclonal antibody. Alemtuzumab binds to CD52, a nonmodulating antige more...

Codimal-LA Codimal-LA
Generic Name: chlorpheniramine and pseudoephedrine (klor fen EER a meen and soo doe e FED rin) Brand Names: Aller-Chlor Decongestant, Allerest Maximum Strength, Anamine, Anaplex, Atrohist Pediatric Capsule, Biohist LA, Brexin L.A., Chlor Trimeton Allergy Decongestant, Chlorafed, Chlordrin more...

Hydroxocobalamin Hydroxocobalamin
Pronouncation: (hye-DROX-oh-koe-BAL-a-min) Class: Antidote Trade Names: Cyanokit - Powder for injection, lyophilized 2.5 g Mechanism of Action Pharmacology Binds with cyanide ions to form cyanocobalamin, which is excreted in the urine. Pharmacokinetics Absorption Following IV administration of hydr more...

Lupron Depot-3 Month 11.25 mg Lupron Depot-3 Month 11.25 mg
Some commonly used brand names are: In the U.S.— Eligard Lupron Lupron Depot Lupron Depot-Ped Lupron Depot-3 Month 11.25 mg Lupron Depot-3 Month 22.5 mg Lupron Depot-4 Month 30 mg Viadur In Canada— Eligard Lupron Lupron Depot Lupron-3 Month SR Depot 22.5 mg Another commonly used more...

Octyl Methoxycinnamate, Octyl Salicylate, Oxybenzone, Padimate O, and Titanium Dioxide Topical Octyl Methoxycinnamate, Octyl Salicylate, Oxybenzone, Padimate O, and Titanium Dioxide Topical
Some commonly used brand names are: In the U.S.— A-Fil 33 Aquaderm Sunscreen Moisturizer 49 Aquaray Sunscreen 42 Bain de Soleil All Day For Kids 38 Bain de Soleil All Day Sunfilter 39 Bain de Soleil Mega Tan 34 Bain de Soleil Orange Gelee 41 Bain de Soleil Sand Buster 41 Bain de Soleil SP more...